NCT02096354View on ClinicalTrials.gov

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 13, 2018

Study Completion Date

October 8, 2020

Conditions
Colorectal Neoplasms
Interventions
DRUG

RRx-001

DRUG

Regorafenib

DRUG

Irinotecan

To be dosed after RRx-001 or regorafenib

Trial Locations (5)

20850

Aquilino Cancer Center, Maryland Oncology and Hematology PA, Rockville

20889

Walter Reed National Military Medical Center, Bethesda

92093

UCSD Moores Cancer Center, La Jolla

94305

Stanford University, Stanford

96819

Kaiser Permanete, Honolulu

Sponsors

Lead Sponsor

EpicentRx, Inc.
All Listed Sponsors
lead

EpicentRx, Inc.

INDUSTRY